结论孟鲁司特钠在慢性阻塞性肺病治疗中临床疗效显著。
Conclusion the clinical efficacy of Montelukast Sodium in the treatment of chronic obstructive pulmonary disease is obvious.
目的：探讨早期口服孟鲁司特钠治疗毛细支气管炎的疗效。
Objective: To investigate the clinical effect of the oral montelukast in early stage of bronchiolitis .
孟鲁司特，选择性白三烯受体1拮抗物，能减少雨蛙肽诱导的胰腺损害。
Montelukast, a Selective Cysteinyl Leukotriene Receptor 1 Antagonist, Reduces Cerulein-Induced Pancreatic Injury in Rats.
男孩经验性地给予每日4毫克的孟鲁司特治疗，4个星期内所有症状皆消失。
The boy was empirically treated with 4 mg daily of Montelukast and all his symptoms resolved within 4 weeks.
孟鲁司特可能通过并影响VEGF及受体的表达影响气道炎症和气道血管重塑的病理生理过程。
MK may be effective in reducing allergic airway inflammation and airway remodeling through VEGF and VEGFR.
孟鲁司特可能通过并影响VEGF及受体的表达影响气道炎症和气道血管重塑的病理生理过程。
MK may be effective in reducing allergic airway inflammation and airway remodeling through VEGF and VEGFR.
应用推荐